Alpha-cell re-generation combined with conversion to beta cells
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Centre National De La Recherche Scientifique, Universite De Nice Sophia Antipolis-Grand ChâTeau
InventorsJacob Hecksher-Sørensen, Patrick Collombat
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with GABA or a GABA receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy.
Claims11
A method for producing a population of pancreatic beta cells comprising the step of contacting a population of alpha cells with (a) GABA or a GABA receptor agonist in combination with (b) a glucagon neutralizing monoclonal antibody, selected from GLU001 or a humanized version thereof, or a glucagon receptor antagonist;
- wherein said glucagon neutralizing monoclonal antibody binds glucagon and said glucagon receptor antagonist binds a glucagon receptor;
- and
- wherein glucagon receptor signaling is decreased or inhibited.
A pharmaceutical composition comprising (a) GABA or a GABA receptor agonist in combination with (b) a glucagon neutralizing monoclonal antibody, selected from GLU001 or a humanized version thereof, or a glucagon receptor antagonist;
- wherein said glucagon neutralizing monoclonal antibody binds glucagon and said glucagon receptor antagonist binds a glucagon receptor;
- and
- wherein glucagon receptor signaling is decreased or inhibited.
A method of treating diabetes in a patient in need thereof comprising a step of administering to said patient an effective amount of a combination of (a) GABA or a GABA receptor agonist with (b) a glucagon neutralizing monoclonal antibody, selected from GLU001 or a humanized version thereof, or a glucagon receptor antagonist;
- wherein said glucagon neutralizing monoclonal antibody binds glucagon and said glucagon receptor antagonist binds a glucagon receptor;
- and
- wherein glucagon receptor signaling is decreased or inhibited.
A method for increasing beta cells mass in a patient in need thereof comprising a step of administering to said patient an effective amount of a combination of (a) GABA or a GABA receptor agonist with (b) a glucagon neutralizing monoclonal antibody, selected from GLU001 or a humanized version thereof, or a glucagon receptor antagonist;
- wherein said glucagon neutralizing monoclonal antibody binds glucagon and said glucagon receptor antagonist binds a glucagon receptor;
- and
- wherein glucagon receptor signaling is decreased or inhibited.
Dependencies are inferred from the claim text.